KR102806779B1 - 시클로펜탄 화합물 - Google Patents

시클로펜탄 화합물 Download PDF

Info

Publication number
KR102806779B1
KR102806779B1 KR1020207035633A KR20207035633A KR102806779B1 KR 102806779 B1 KR102806779 B1 KR 102806779B1 KR 1020207035633 A KR1020207035633 A KR 1020207035633A KR 20207035633 A KR20207035633 A KR 20207035633A KR 102806779 B1 KR102806779 B1 KR 102806779B1
Authority
KR
South Korea
Prior art keywords
fluorophenyl
cyclopentyl
compound
piperidin
piperidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035633A
Other languages
English (en)
Korean (ko)
Other versions
KR20210018287A (ko
Inventor
샤오린 장
웨이타오 판
그리고리오스 니키티디스
제니 수잔나 마리카 린드하겐
Original Assignee
디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 filed Critical 디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Publication of KR20210018287A publication Critical patent/KR20210018287A/ko
Application granted granted Critical
Publication of KR102806779B1 publication Critical patent/KR102806779B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020207035633A 2018-05-11 2019-05-09 시클로펜탄 화합물 Active KR102806779B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/086503 2018-05-11
CN2018086503 2018-05-11
PCT/EP2019/061888 WO2019215268A1 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Publications (2)

Publication Number Publication Date
KR20210018287A KR20210018287A (ko) 2021-02-17
KR102806779B1 true KR102806779B1 (ko) 2025-05-12

Family

ID=66542241

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035633A Active KR102806779B1 (ko) 2018-05-11 2019-05-09 시클로펜탄 화합물

Country Status (16)

Country Link
US (2) US11274091B2 (https=)
EP (1) EP3790870B1 (https=)
JP (1) JP7418354B2 (https=)
KR (1) KR102806779B1 (https=)
CN (1) CN112424182B (https=)
AR (1) AR115382A1 (https=)
AU (1) AU2019266525B2 (https=)
BR (1) BR112020023065A2 (https=)
CA (1) CA3099507A1 (https=)
DK (1) DK3790870T3 (https=)
ES (1) ES2944735T3 (https=)
MX (1) MX2020012065A (https=)
PT (1) PT3790870T (https=)
TW (1) TWI830733B (https=)
UY (1) UY38229A (https=)
WO (1) WO2019215268A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物
JP7594274B2 (ja) 2019-10-24 2024-12-04 国立大学法人大阪大学 難聴の予防および/または治療用医薬組成物
WO2025008249A1 (en) 2023-07-06 2025-01-09 Basf Se Triazole compounds for the control of invertebrate pests

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006001958A2 (en) * 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
EP2049500B1 (en) * 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN102015708B (zh) * 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
PT2370442E (pt) * 2008-11-26 2013-06-27 Pfizer 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2368876A1 (en) 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
CN105308040B (zh) * 2013-06-21 2019-06-04 默克专利股份公司 1,3-二氨基环戊烷甲酰胺衍生物
SG11201600726QA (en) * 2013-07-29 2016-03-30 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物

Also Published As

Publication number Publication date
UY38229A (es) 2019-11-29
AR115382A1 (es) 2021-01-13
JP2021523178A (ja) 2021-09-02
US12378218B2 (en) 2025-08-05
AU2019266525A1 (en) 2020-11-26
EP3790870B1 (en) 2023-04-19
EP3790870A1 (en) 2021-03-17
BR112020023065A2 (pt) 2021-02-02
KR20210018287A (ko) 2021-02-17
PT3790870T (pt) 2023-05-05
US20210070733A1 (en) 2021-03-11
CN112424182B (zh) 2023-05-23
AU2019266525B2 (en) 2024-06-13
CA3099507A1 (en) 2019-11-14
US20220194922A1 (en) 2022-06-23
JP7418354B2 (ja) 2024-01-19
MX2020012065A (es) 2021-02-26
TW202016087A (zh) 2020-05-01
US11274091B2 (en) 2022-03-15
ES2944735T3 (es) 2023-06-23
DK3790870T3 (da) 2023-05-08
CN112424182A (zh) 2021-02-26
WO2019215268A1 (en) 2019-11-14
TWI830733B (zh) 2024-02-01

Similar Documents

Publication Publication Date Title
CN104418860B (zh) 嘧啶并杂环类化合物及其药用组合物和应用
US12378218B2 (en) Cyclopentane compounds
EP3773555A1 (en) Factor xiia inhibitors
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
CN108699035A (zh) 新化合物
JP2017509685A (ja) 大環状ピリジン誘導体
JP2022533147A (ja) 芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用
IL283397B2 (en) Heteroaromatic compounds as vanin inhibitors
EP2864296A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
CN116685313A (zh) 用于治疗神经变性疾病的含有茚满基的羧酸化合物
CN115996908B (zh) Gpr39蛋白的拮抗剂
EP3253761A1 (en) 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
WO2020021015A1 (en) New imidazopyridine derivatives for treating pain and pain related conditions
CN107344942B (zh) 调节电压门控钠通道的化合物
RU2794997C9 (ru) Соединения циклопентана
RU2794997C2 (ru) Соединения циклопентана
WO2024233742A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
HK40047027B (en) Cyclopentane compounds
HK40047027A (en) Cyclopentane compounds
HK40047026A (en) Cyclopentane compounds
CN121219279A (zh) 磺酰胺及砜的氟化环状衍生物以及其组成物与方法
JPWO2021222858A5 (https=)
WO2025160220A2 (en) Tead inhibitors and methods of use
EP4709486A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
JP2024534757A (ja) Pd-l1相互作用の免疫調節剤としての化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000